查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933325

全球心肌肌鈣蛋白市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析及預測（2026-2034 年）

Cardiac Troponin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

心肌肌鈣蛋白市場成長驅動因子

全球心肌肌鈣蛋白市場正經歷強勁成長，其主要驅動因素包括心血管疾病盛行率的上升、先進診斷技術的廣泛應用以及對早期檢測心肌損傷的日益重視。心肌肌鈣蛋白是一種高度特異性的生物標記物，用於診斷心肌梗塞 (MI) 和急性冠狀動脈綜合症 (ACS)。它能夠檢測到最細微的心肌損傷，使其成為急診和重症監護環境中不可或缺的工具。

預計到 2025 年，全球心肌肌鈣蛋白市場規模將達到 35 億美元。預計到2026年，市場規模將成長至37.8億美元，到2034年將進一步擴大至71.7億美元，2026年至2034年的複合年增長率（CAGR）為8.30%。這一穩步增長反映了全球心臟相關疾病負擔的日益加重以及高靈敏度檢測解決方案的不斷發展。

市場驅動因素

心血管疾病（CVD）盛行率的不斷上升仍然是心肌肌鈣蛋白市場的主要驅動因素。根據美國疾病管制與預防中心（CDC）統計，美國每40秒就有一人發生心臟病發作，凸顯了快速準確診斷工具的緊迫性。肌鈣蛋白水平升高與心肌損傷直接相關，肌鈣蛋白檢測已成為診斷心臟病發作和監測疾病進展的標準流程。

此外，全球人口老化也顯著推動了市場成長。老年人更容易罹患高血壓、冠狀動脈疾病和心臟衰竭等慢性疾病。人口老化加劇導致住院率上升，並增加了對心臟生物標記檢測（包括肌鈣蛋白檢測）的需求。

市場趨勢

影響市場的主要趨勢包括高靈敏度肌鈣蛋白檢測和即時檢測（POC​​）肌鈣蛋白檢測的日益普及。這些先進的檢測方法能夠更快地獲得結果，並提高診斷準確性，尤其是在急診室。高靈敏度檢測可以檢測到極低濃度的肌鈣蛋白，從而實現心肌梗塞的早期發現，並區分急性和慢性心臟疾病。

技術進步和監管審批進一步加速了這一趨勢的普及。例如，美國食品藥物管理局（FDA）批准高靈敏度肌鈣蛋白檢測，增強了其臨床接受度，並擴大了其在常規心臟診斷中的應用。

限制因子

儘管市場成長前景廣闊，但傳統肌鈣蛋白檢測的敏感度限制仍構成挑戰。傳統檢測方法無法檢測到心肌損傷早期階段的低濃度肌鈣蛋白，可能導致診斷延遲。這項限制凸顯了高靈敏度檢測方法的必要性，同時也阻礙了其在新技術普及率較低的地區的廣泛應用。

市場區隔分析

依類型劃分，市場可分為肌鈣蛋白 I 和肌鈣蛋白 T。肌鈣蛋白 I 市場佔主導地位，預計到 2026 年將佔全球 73.32% 的市場佔有率，這主要歸功於其較高的心臟特異性以及在心肌梗塞診斷中的廣泛應用。由於監管審批的增加及其在心臟衰竭篩檢中作用的擴大，肌鈣蛋白T市場預計將穩定成長。

依應用環境劃分，市場可分為實驗室檢測與即時檢測（POC​​）。實驗室檢測佔最大的市場佔有率，預計到2026年將達到73.68%，主要得益於其高精度和詳細的定量分析。然而，由於在急診護理和資源匱乏地區使用量的增加，即時檢測 (POC) 細分市場預計將以更快的速度成長。

依最終用戶劃分，醫院和診所將在 2026 年佔市場主導地位，市佔率達 63.44%。這主要歸功於患者入院人數眾多以及肌鈣蛋白檢測在急診心臟護理的廣泛應用。

區域洞察

北美將在 2025 年引領全球心臟肌鈣蛋白市場，佔 41.15% 的市場佔有率，並創造 14.4 億美元的收入。該地區受益於先進的醫療基礎設施、有利的報銷政策以及高靈敏度檢測方法的廣泛應用。預計到 2026 年，美國市場規模將達到 14 億美元。

歐洲將佔第二大市場佔有率，這得益於 CE 認證的高靈敏度檢測方法的廣泛應用以及健全的監管框架。由於心血管疾病盛行率上升、診斷基礎設施不斷完善以及公眾意識不斷增強，亞太地區預計將成為成長最快的地區。到2026年，中國、日本和印度的市場規模預計將分別達到2.8億美元、1.9億美元和1.4億美元。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家和地區主要心血管疾病盛行率（2024/2025）
  • 心臟肌鈣蛋白檢測技術進展
  • 主要公司新產品發布
  • 關鍵產業趨勢：併購、業務合作等
  • 新冠疫情的影響市場

第五章 全球心肌肌鈣蛋白市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • 肌鈣蛋白T
    • 肌鈣蛋白I
  • 市場分析、洞察與預測：依安裝環境劃分
    • 實驗室檢測
    • 即時偵測 (POC)
  • 市場分析、洞察與預測：依適應症劃分
    • 心肌梗塞
    • 充血性心臟衰竭
    • 急性冠狀動脈綜合症
    • 其他
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院和診所
    • 診斷實驗室
    • 家庭醫療保健，其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美心肌肌鈣蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲心肌肌鈣蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家

第八章：亞太地區心肌肌鈣蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區

第九章：拉丁美洲心肌肌鈣蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲心肌肌鈣蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 世界市場佔有率分析(2025年)
  • 企業簡介
    • F. Hoffmann-La Roche Ltd.
    • bioMerieux SA
    • Abbott
    • Siemens Healthineers AG
    • Eurolyser Diagnostica GmbH
    • QuidelOrtho(Quidel Corporation)
    • PerkinElmer Inc.
    • Beckman Coulter, Inc.(Danaher)
    • RESPONSE BIOMEDICAL
    • LifeSign LLC.
Product Code: FBI101234

Growth Factors of cardiac troponin Market

The global cardiac troponin market is witnessing robust growth, driven by the rising prevalence of cardiovascular diseases, growing adoption of advanced diagnostic technologies, and increasing emphasis on early detection of myocardial injury. Cardiac troponin is a highly specific biomarker used for the diagnosis of myocardial infarction (MI) and acute coronary syndromes (ACS). Its ability to detect even minimal cardiac muscle damage has made it an indispensable tool in emergency and critical care settings.

In 2025, the global cardiac troponin market was valued at USD 3.50 billion. The market is projected to grow to USD 3.78 billion in 2026 and further expand to USD 7.17 billion by 2034, registering a CAGR of 8.30% from 2026 to 2034. This steady expansion reflects the increasing burden of heart-related disorders worldwide and the continuous evolution of high-sensitivity testing solutions.

Market Drivers

The growing prevalence of cardiovascular diseases (CVDs) remains the primary driver of the cardiac troponin market. According to the Centers for Disease Control and Prevention (CDC), in the U.S., one person experiences a heart attack every 40 seconds, highlighting the urgent need for rapid and accurate diagnostic tools. Elevated troponin levels are directly linked to myocardial injury, making troponin testing a standard protocol for diagnosing heart attacks and monitoring disease progression.

Additionally, the aging global population is significantly contributing to market growth. Older adults are more susceptible to chronic conditions such as hypertension, coronary artery disease, and heart failure. The increasing geriatric population is driving higher hospitalization rates and demand for cardiac biomarker testing, including troponin assays.

Market Trends

A key trend shaping the market is the increasing adoption of high-sensitivity and point-of-care (POC) troponin tests. These advanced tests enable faster turnaround times and improved diagnostic accuracy, particularly in emergency departments. High-sensitivity assays can detect very low levels of troponin, allowing early identification of myocardial infarction and differentiation between acute and chronic cardiac conditions.

Technological advancements and regulatory approvals are further accelerating adoption. For instance, the U.S. FDA's approval of high-sensitivity troponin assays has strengthened their clinical acceptance and expanded their use in routine cardiac diagnostics.

Restraining Factors

Despite strong growth prospects, the market faces challenges related to the limited sensitivity of conventional troponin assays. Traditional tests may fail to detect low troponin concentrations during the early hours following myocardial injury, potentially delaying diagnosis. This limitation underscores the need for advanced high-sensitivity assays but also restricts adoption in regions with limited access to newer technologies.

Segmentation Analysis

By type, the market is segmented into troponin I and troponin T. The troponin I segment dominated the market in 2026, accounting for 73.32% of the global share, due to its high cardiac specificity and widespread use in MI diagnosis. The troponin T segment is expected to witness steady growth, supported by increasing regulatory approvals and its expanding role in heart failure screening.

Based on setting, the market is divided into laboratory testing and point-of-care testing. Laboratory testing held the largest share in 2026 at 73.68%, driven by higher accuracy and detailed quantitative analysis. However, the POC testing segment is expected to grow at a faster rate due to increasing use in emergency and resource-limited settings.

By end user, hospitals and clinics dominated the market with a 63.44% share in 2026, owing to high patient admissions and extensive use of troponin tests in emergency cardiac care.

Regional Insights

North America dominated the global cardiac troponin market in 2025, accounting for 41.15% share and generating USD 1.44 billion in revenue. The region benefits from advanced healthcare infrastructure, favorable reimbursement policies, and high adoption of high-sensitivity assays. The U.S. market is projected to reach USD 1.40 billion by 2026.

Europe held the second-largest share, supported by widespread adoption of CE-marked high-sensitivity assays and strong regulatory frameworks. Asia Pacific is anticipated to be the fastest-growing region due to rising cardiovascular disease prevalence, expanding diagnostic infrastructure, and increasing awareness. By 2026, China, Japan, and India are projected to reach USD 0.28 billion, USD 0.19 billion, and USD 0.14 billion, respectively.

Competitive Landscape

The cardiac troponin market is moderately competitive, with key players focusing on product innovation, regulatory approvals, and strategic collaborations. F. Hoffmann-La Roche Ltd. leads the market due to its strong high-sensitivity troponin portfolio. Other prominent players include Abbott, Siemens Healthineers, bioMerieux, Beckman Coulter, and QuidelOrtho.

Conclusion

The global cardiac troponin market is poised for strong and sustained growth over the forecast period, driven by the rising burden of cardiovascular diseases, expanding geriatric population, and rapid adoption of high-sensitivity and point-of-care diagnostic technologies. From a market size of USD 3.50 billion in 2025, the industry is expected to reach USD 7.17 billion by 2034. While limitations of conventional assays remain a challenge, continuous technological advancements, increasing regulatory approvals, and growing emphasis on early cardiac diagnosis are expected to unlock significant growth opportunities. Overall, cardiac troponin testing will remain a cornerstone of modern cardiovascular diagnostics worldwide.

Segmentation

By Type

  • Troponin T
  • Troponin I

By Setting

  • Laboratory Testing
  • Point-of-Care (POC) Testing

By Indication

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Others

By End User

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Homecare Settings & Others

By Region

  • North America ( By Type, By Setting, By Indication, By End User, By Country)
    • U.S.
    • Canada
  • Europe ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Cardiovascular Diseases, By Key Countries/Regions, 2024/2025
  • 4.2. Technological Advancements in Cardiac Troponin Testing
  • 4.3. New Product Launches. By Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Troponin T
    • 5.1.2. Troponin I
  • 5.2. Market Analysis, Insights and Forecast - By Setting
    • 5.2.1. Laboratory Testing
    • 5.2.2. Point-of-Care (POC) Testing
  • 5.3. Market Analysis, Insights and Forecast - By Indication
    • 5.3.1. Myocardial Infarction
    • 5.3.2. Congestive Heart Failure
    • 5.3.3. Acute Coronary Syndrome
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By End-User
    • 5.4.1. Hospitals & Clinics
    • 5.4.2. Diagnostic Laboratories
    • 5.4.3. Homecare Settings & Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Troponin T
    • 6.1.2. Troponin I
  • 6.2. Market Analysis, Insights and Forecast - By Setting
    • 6.2.1. Laboratory Testing
    • 6.2.2. Point-of-Care (POC) Testing
  • 6.3. Market Analysis, Insights and Forecast - By Indication
    • 6.3.1. Myocardial Infarction
    • 6.3.2. Congestive Heart Failure
    • 6.3.3. Acute Coronary Syndrome
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By End-User
    • 6.4.1. Hospitals & Clinics
    • 6.4.2. Diagnostic Laboratories
    • 6.4.3. Homecare Settings & Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Troponin T
    • 7.1.2. Troponin I
  • 7.2. Market Analysis, Insights and Forecast - By Setting
    • 7.2.1. Laboratory Testing
    • 7.2.2. Point-of-Care (POC) Testing
  • 7.3. Market Analysis, Insights and Forecast - By Indication
    • 7.3.1. Myocardial Infarction
    • 7.3.2. Congestive Heart Failure
    • 7.3.3. Acute Coronary Syndrome
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By End-User
    • 7.4.1. Hospitals & Clinics
    • 7.4.2. Diagnostic Laboratories
    • 7.4.3. Homecare Settings & Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Rest of Europe

8. Asia Pacific Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Troponin T
    • 8.1.2. Troponin I
  • 8.2. Market Analysis, Insights and Forecast - By Setting
    • 8.2.1. Laboratory Testing
    • 8.2.2. Point-of-Care (POC) Testing
  • 8.3. Market Analysis, Insights and Forecast - By Indication
    • 8.3.1. Myocardial Infarction
    • 8.3.2. Congestive Heart Failure
    • 8.3.3. Acute Coronary Syndrome
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By End-User
    • 8.4.1. Hospitals & Clinics
    • 8.4.2. Diagnostic Laboratories
    • 8.4.3. Homecare Settings & Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. China
    • 8.5.2. India
    • 8.5.3. Japan
    • 8.5.4. Australia
    • 8.5.5. Rest of Asia Pacific

9. Latin America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Troponin T
    • 9.1.2. Troponin I
  • 9.2. Market Analysis, Insights and Forecast - By Setting
    • 9.2.1. Laboratory Testing
    • 9.2.2. Point-of-Care (POC) Testing
  • 9.3. Market Analysis, Insights and Forecast - By Indication
    • 9.3.1. Myocardial Infarction
    • 9.3.2. Congestive Heart Failure
    • 9.3.3. Acute Coronary Syndrome
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By End-User
    • 9.4.1. Hospitals & Clinics
    • 9.4.2. Diagnostic Laboratories
    • 9.4.3. Homecare Settings & Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Troponin T
    • 10.1.2. Troponin I
  • 10.2. Market Analysis, Insights and Forecast - By Setting
    • 10.2.1. Laboratory Testing
    • 10.2.2. Point-of-Care (POC) Testing
  • 10.3. Market Analysis, Insights and Forecast - By Indication
    • 10.3.1. Myocardial Infarction
    • 10.3.2. Congestive Heart Failure
    • 10.3.3. Acute Coronary Syndrome
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By End-User
    • 10.4.1. Hospitals & Clinics
    • 10.4.2. Diagnostic Laboratories
    • 10.4.3. Homecare Settings & Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. bioMerieux SA
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Abbott
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Siemens Healthineers AG
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Eurolyser Diagnostica GmbH
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. QuidelOrtho (Quidel Corporation)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. PerkinElmer Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Beckman Coulter, Inc. (Danaher)
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. RESPONSE BIOMEDICAL
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. financials (Based on Availability)
    • 11.2.10. LifeSign LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. financials (Based on Availability)

List of Tables

  • Table 1: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 3: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 4: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 5: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 7: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 8: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 9: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 10: North America Cardiac Troponin Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 12: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 13: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 14: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 15: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 18: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 19: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 20: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 23: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 24: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 25: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 27: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 28: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 29: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 30: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cardiac Troponin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cardiac Troponin Market Value Share (%), By Type, 2025 & 2034
  • Figure 3: Global Cardiac Troponin Market Value Share (%), by Setting, 2025 & 2034
  • Figure 4: Global Cardiac Troponin Market Value Share (%), by Indication, 2025 & 2034
  • Figure 5: Global Cardiac Troponin Market Value Share (%), by End-User, 2025 & 2034
  • Figure 6: Global Cardiac Troponin Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 8: North America Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 9: North America Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 10: North America Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 11: North America Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 12: North America Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 13: North America Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 14: North America Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 15: North America Cardiac Troponin Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Cardiac Troponin Market Value Share (%), By Country, 2025
  • Figure 17: Europe Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 18: Europe Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 19: Europe Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 20: Europe Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 21: Europe Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 22: Europe Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 23: Europe Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 24: Europe Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 25: Europe Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 28: Asia Pacific Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 29: Asia Pacific Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 30: Asia Pacific Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 31: Asia Pacific Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 32: Asia Pacific Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 33: Asia Pacific Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 34: Asia Pacific Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 35: Asia Pacific Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 38: Latin America Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 39: Latin America Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 40: Latin America Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 41: Latin America Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 42: Latin America Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 43: Latin America Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 44: Latin America Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 45: Latin America Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 48: Middle East & Africa Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 49: Middle East & Africa Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 50: Middle East & Africa Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 51: Middle East & Africa Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 53: Middle East & Africa Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 54: Middle East & Africa Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 55: Middle East & Africa Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034s
  • Figure 56: Middle East & Africa Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Cardiac Troponin Market Share (%), By Company, 2025